Revenue: As of FY2025, the actual value is USD 2.14 M.EPS: As of FY2025, the actual value is USD -0.99.EBIT: As of FY2025, the actual value is USD -10.28 M.<h3>Segment Revenue</h3><ul><li>Pocono Pharmaceuticals: Revenue for the year ending January 31, 2025, was $2,139,537, compared to $1,920,280 for the year ending January 31, 2024.</li><li>4P Therapeutics: No revenue was generated for the year ending January 31, 2025, compared to $165,034 for the year ending January 31, 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: Pocono Pharmaceuticals reported a gross profit of $743,317 for the year ending January 31, 2025, compared to $744,391 for the year ending January 31, 2024.</li><li>Selling, General and Administrative Expenses: Pocono Pharmaceuticals incurred $661,805 in expenses for the year ending January 31, 2025, compared to $606,275 for the year ending January 31, 2024.</li><li>Research and Development: 4P Therapeutics incurred $3,119,134 in research and development expenses for the year ending January 31, 2025, compared to $1,960,425 for the year ending January 31, 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: The company used cash of - $4,626,564 in operations for the year ending January 31, 2025.</li><li>Investing Cash Flow: Cash used in investing activities was - $92,043 for the year ending January 31, 2025.</li><li>Financing Cash Flow: Cash provided by financing activities was $8,537,384 for the year ending January 31, 2025.</li></ul><h3>Unique Metrics</h3><ul><li>Impairment Charge: The company recorded an impairment charge of $3,595,216 for the year ending January 31, 2025, reducing the value of its goodwill and intangible assets.</li></ul><h3>Outlook / Guidance</h3><ul><li>The company plans to continue the development of its AVERSA Fentanyl product, with an estimated budget of $3.2 million through NDA submission following an amended agreement with Kindeva Drug Delivery.</li></ul>

NUTRIBAND INC C/WTS (TO PUR COM) | 10-K: FY2025 Revenue: USD 2.14 M